I’ve been manufacturing hemp gummies in Louisville since 2016. The question I hear from almost every retail buyer who is already carrying CBD: “I’ve got CBD. Why do I need CBG?”

It is the right question. Here is the direct answer: CBD and CBG are not the same use occasion, not the same consumer, and not the same retail position. A retailer with both covers two time-of-day occasions and two purchase motivations that do not overlap in any meaningful way. A retailer with only CBD is leaving the daytime-use wellness segment to a competitor.

The one-line version: CBD is general wellness — broad demographic, morning or any-time use. CBG is daytime-use wellness — a distinct use occasion, a distinct customer query, and a more expensive ingredient that carries better retail economics. They do not cannibalize each other. They expand the category.

What Makes CBG Different from CBD — The Brief Chemistry

CBD and CBG are both hemp-derived cannabinoids. They are different molecules with different biosynthetic origins.

The relevant distinction: the hemp plant produces CBGA (cannabigerolic acid) first. CBGA is the molecular precursor. As the plant matures, enzymes convert CBGA into THCA, CBDA, and CBCA — the acid precursors to THC, CBD, and CBC. By the time a hemp plant reaches full maturity, almost all of the CBGA has already converted. Very little CBG remains.

This is why CBG costs more. Cultivators must either harvest early (when CBGA has not yet fully converted), breed strains selected for high CBG expression at maturity, or accept low-yield extraction from mature biomass. Any of those routes costs more than conventional hemp-for-CBD production. That cost is real and it flows through the supply chain to the finished product price.

CBG is non-intoxicating. It is not a THC analog. It does not produce psychoactive effects. This is consistent with the limited preliminary research that exists on CBG.

For the full CBG primer — cultivation economics, COA requirements, H.R. 5371 compliance, wholesale dosing ranges — see What Is CBG?.

Different Use Occasions, Different Consumer Searches

The retail logic for carrying both CBD and CBG comes down to use occasion and search intent.

CBD is the general wellness cannabinoid. The consumer reaching for CBD is often not thinking about a specific time of day. It is a broad-appeal, well-understood ingredient with a decade of consumer education behind it. Your CBD SKUs serve the widest possible audience.

CBG is positioning toward daytime-use wellness.

^ These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

The consumer reaching for CBG has typically already tried CBD and is looking for something with a daytime-specific identity — something that fits into a morning or workday routine rather than a general supplement rotation.

The search data reflects this. “What is CBG” and “CBG gummies” are not the same search as “CBD gummies.” The consumer querying CBG has a more specific intent — they are looking for something daytime, something with what the market has positioned as functional wellness, something adjacent to L-theanine and lion’s mane rather than general supplement support.

This means your CBG SKU is not just a variation on your CBD shelf. It is capturing a different search, a different customer, and a different purchase motivation. At retail, those are two separate shelf positions.

The Margin Case for CBG

CBG is more expensive than CBD. That is not a problem — it is an opportunity.

Because CBG costs more to source and manufacture, it carries a higher retail price. That higher price sits with consumers in the functional supplement segment, who are already accustomed to paying premium prices for specialty ingredients (lion’s mane, NMN, clinical-dose L-theanine). The margin structure on a CBG SKU can be meaningfully stronger than a commodity CBD product — not because you are inflating the price, but because the ingredient cost, the category positioning, and the consumer expectation all support a premium price point.

The rough economics: CBD gummies at standard wholesale pricing are a competitive, price-sensitive category. The market has been compressing CBD margins for several years. CBG has not followed that trajectory because the source material is more expensive and the supply chain is shorter. In our wholesale accounts, adding a CBG SKU alongside CBD has tended to improve overall hemp-category margin even when CBG moves fewer units than CBD.

Any wholesale pricing claims on CBG need to be verified against current market conditions. Our current wholesale pricing and minimum order quantities are at /wholesale-pricing/ — we update that as sourcing costs change.

Shelf Positioning: Where Each Product Lives

The category-expansion play requires two distinct shelf positions. Not side by side in the same section. Adjacent to different neighbors.

Where to stock CBD: - General wellness section - Alongside magnesium, ashwagandha, adaptogens, omega-3 - Morning-any-time framing - Appeal: broad demographic, including consumers new to hemp

Where to stock CBG: - Daytime functional supplement section - Alongside L-theanine, lion’s mane, Rhodiola, clean-energy formulas - Morning or midday use occasion framing - Appeal: supplement-literate consumer who has already explored CBD and is looking for the next layer

The adjacency matters because it tells the consumer what the product is before they read the label. A CBG gummy sitting next to lion’s mane communicates “daytime-use wellness.” The same product sitting in a general CBD display communicates nothing distinctive and loses the positioning advantage.

For the consumer who is in the store for CBD and notices the CBG, the shelf geography opens the cross-sell. That is the next section.

The Cross-Sell: Turning CBD Customers into CBG Customers

A customer who is already buying your CBD product is your highest-probability CBG prospect. They trust hemp-derived cannabinoids. They are supplement-literate. They are already in your store. They are looking at your shelf.

The cross-sell requires one thing: a staff member who can explain the distinction without making medical claims and without making the customer feel like they are being upsold on something unnecessary.

Here is the scripted line:

“The CBD you’re getting is great for general routine use — it’s the foundational cannabinoid for most people. CBG is a different molecule that’s specifically positioned for daytime use. Some customers run CBD in the evening and try CBG in the morning as a complement. They’re different ingredients for different times of day.”

That is accurate, compliant, and positions CBG as an addition — not a replacement — to what the customer already trusts. You are not telling the customer their CBD is inadequate. You are expanding their routine.

^ These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Additional cross-sell context for staff: a customer who has been using CBD for a while and is curious about trying a different cannabinoid is often ready to explore CBG. It is not a clinical upgrade. It is a category exploration that supplement retailers do routinely with other ingredient categories.

Frequently Asked Questions

Can I pitch CBG to my existing CBD customer?

Yes, and those customers are your best CBG prospects. They already understand hemp-derived cannabinoids, they already trust your hemp section, and they are likely looking for something to complement their CBD routine. The pitch is simple: different use occasion, different time of day. Do not position CBG as better than CBD — position it as different.

Is CBG a better seller than CBD?

Not typically by volume. CBD has broader consumer familiarity and a larger addressable market. What CBG can do is carry better per-unit economics and fill a distinct shelf position that CBD does not cover. The right benchmark for CBG is not “does it outsell CBD” — it is “does it expand my hemp category revenue and margin beyond what CBD alone would generate.” In our wholesale accounts, adding a CBG SKU alongside CBD has tended to expand total hemp-category revenue rather than leaving it flat.

Do I need both products to position hemp properly?

You can operate a successful hemp set with CBD alone. But a retailer with only CBD is leaving the daytime-use wellness occasion and the premium-ingredient consumer segment underserved. Whether you add CBG depends on your channel, your consumer base, and your willingness to staff a slightly more complex shelf story. If your staff can explain the use-occasion distinction in one sentence, you are ready for both.

What’s the typical SKU count split between CBD and CBG in a mature hemp set?

There is no industry-wide standard. What we see in channels that have built out cannabinoid sets: CBD SKUs typically outnumber CBG SKUs 3-to-1 or 4-to-1, reflecting the broader consumer base for CBD. A retailer with 4 CBD SKUs might carry 1–2 CBG SKUs. That ratio gives you enough variety on the CBG side to offer dosing options without overcommitting shelf space to a category you are still developing.

Does CBG cannibalize CBD sales?

Anecdotally, no — because the use occasions are different. A customer adding CBG to their morning routine is not typically reducing their CBD purchase. The occasions do not overlap the way, say, two identically positioned CBD oils might. The caveat: if you position CBG as a daytime alternative to your CBD oil without making the use-occasion distinction clear, you may see some switching. The shelf position and staff talk matter. Keep the occasions distinct and cannibalization is unlikely.

Sources

  1. U.S. Congress. H.R. 5371 — Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act. Congress.gov
  2. Russo, E.B. et al. “Cannabidiol and Other Cannabinoids: Research and Clinical Perspectives.” Frontiers in Neuroscience. (Cited for general cannabinoid chemistry background — not as evidence of consumer outcomes for CBG or CBD.)
  3. Aizpurua-Olaizola, O. et al. “Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes.” Journal of Natural Products (2016). (Cited for CBGA biosynthesis pathway — not as evidence of health outcomes.)
  4. Congressional Research Service. “Hemp as an Agricultural Commodity.” CRS Report RL32725. CRS.gov

Ready to add CBG to your existing hemp set? Request a wholesale quote and we’ll put together options within one business day. If you want to look at bulk CBG gummies for your own packaging, details are at /bulk-cbg-gummies-wholesale/.

These statements have not been evaluated by the FDA. Our products are not intended to diagnose, treat, cure, or prevent any disease.